

## VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001023

Report Form

## Serious Adverse Event Report Form

Please send this report immediately to Assign Safety Desk via:

Fax: +43 (0) 512 281514 77 or e-mail: [SafetyDesk@assigndmb.com](mailto:SafetyDesk@assigndmb.com)

(24h Safety Hotline: +43 (0) 676 844033835)

All dates should be provided as DD/MMM/YYYY.

<b>1. PROTOCOL INFORMATION:</b>		
Protocol Short Title:	VLN Cigarette Consumption Study	IND no.: N/A
Celerion Protocol no.:	CA24914	Country: USA
<b>2. REPORTER'S DETAILS:</b>		
Reporter's name:	(b) (6)	
Address:	621 Rosa St. Lincoln, NE 68502	
Site:	LNK Celerion	
Email:	(b) (6) @celerion.com	
Phone/Fax:	(b) (6)	
<b>3. REPORT INFORMATION:</b> (please use the same form for initial and follow-up report, if possible)		
Initial Report:	Date: 11 SEP 2018	(b) (6)
	dd mmm yyyy	Reporter's name and Signature
Follow-Up No 1:	Date: 10 OCT 2018	(b) (6)
	dd mmm yyyy	Reporter's name and Signature
Follow-Up No ____:	Date: ____ ____ 20 ____	Reporter's name and Signature
	dd mmm yyyy	Reporter's name and Signature
Follow-Up No ____:	Date: ____ ____ 20 ____	Reporter's name and Signature
	dd mmm yyyy	Reporter's name and Signature
<b>4. SUBJECT INFORMATION:</b>		
Date of birth:	Race:	Height:
(b) (6)	<input checked="" type="checkbox"/> White/Caucasian	1.61 cm
dd mmm yyyy	<input type="checkbox"/> Black/African American	
	<input type="checkbox"/> Asian	
Gender:	<input type="checkbox"/> Native Hawaiian/other Pacific Islander	Weight:
<input checked="" type="checkbox"/> female	<input type="checkbox"/> American Indian/Alaska Native	162.6 kg
<input type="checkbox"/> male	<input type="checkbox"/> Other:	

## VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001073

Report Form

## 5. SERIOUS ADVERSE EVENT: (short term; please provide ONE diagnosis, if possible)

intra cranial  
aneurysm

## 6. SERIOUS ADVERSE EVENT INFORMATION:

Awareness date: 11 SEP 2018 dd mmm yyyy *Date the investigator became aware of the event*

Onset date of event: (b) (6) dd mmm yyyy *Date the event started, i.e. the first symptoms occurred*

Stop date of event: 20 dd mmm yyyy *Date, when the event (including symptoms) subsided, stabilized with sequelae, or date of subject's death*

## 7. SEVERITY OF SAE:

☐ Mild
 ☐ Moderate
 ☒ Severe
8. SERIOUSNESS CRITERIA: (please tick all that apply) ☐ yes ☐ no (non-serious event of special interest)

- ☒ Inpatient hospitalization or prolongation of existing hospitalization\* ☐ Persistent or significant disability/incapacity or substantial interruption to conduct normal life functions
- ☐ Congenital anomaly/birth defect ☒ Life-threatening
- ☐ Important medical event ☐ Death\*\*  
(Please specify in the SAE description field on page 3 and only tick this criterion if no other applies)

\* if hospitalization: Date of admission: (b) (6) dd mmm yyyy Date of discharge: 20 dd mmm yyyy

\*\* if death: Date of death: 20 dd mmm yyyy

Probable cause of death: \_\_\_\_\_ Autopsy performed? ☐ yes ☐ no  
(if yes, please provide summary of autopsy report in the SAE description on page 3)

## 9. SAE OUTCOME: (please tick only one)

- ☒ resolved ☐ worse
- ☐ improved ☐ fatal
- ☐ unchanged ☐ unknown/lost to follow-up

## VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001023

Report Form

## 10. STUDY PRODUCT INFORMATION:

Study product name	First use			Last use prior to SAE		
	dd	mmm	yyyy	dd	mmm	yyyy
<input type="checkbox"/> Subject's usual brand non-mentholated filtered king size cigarettes			20			20
<input type="checkbox"/> Subject's usual brand mentholated filtered king size cigarettes			20			20
<input checked="" type="checkbox"/> Non-mentholated VLN cigarettes	02	AUG	2018	14	SEP	2018
<input type="checkbox"/> Mentholated VLN cigarettes			20			20

## 11. ASSESSMENT OF CAUSALITY:

☐ likely      ☐ probably      ☐ possibly      ☒ unlikely      ☐ unrelated

## 12. ACTION TAKEN WITH STUDY PRODUCT: (please tick only one)

☐ Unchanged      ☐ Interrupted      ☐ Reduced      ☒ Withdrawn

## 13. ACTION TAKEN TO TREAT SAE:

☐ none  
☐ drug therapy started  
☐ diagnostic test performed  
☐ non-drug therapy started  
☒ unknown

☐ other (please specify):

## 14. SERIOUS ADVERSE EVENT DESCRIPTION:

Describe event fully. Include baseline medical status (medical history, signs and symptoms, diagnosis, diagnostic test results, clinical course, treatment (all drugs/procedures used as interventions for SAE), outcome, hospital course for hospitalizations, etc.  
Please do not attach test results and hospital records but provide a short summary of relevant findings. Please also provide rationale for relationship assessment.

10 OCT 2018 : Subject returned on 10-OCT-2018 to sign medical release form. Dr. Mathew discussed events leading up to the SAE. Subject reports sudden onset of unconsciousness on (b) (6). Upon regaining consciousness, she noticed she had vomited and had a severe headache. She was evaluated at the hospital but then transported via ambulance to a larger ICU hospital and was surgically treated for a



## VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001023

Report Form

intracranial aneurysm.

## 15. INVESTIGATOR'S SIGNATURE:

Investigator's name: PHILIP MATHEW

Investigator's signature:

(b) (6)

Date:

10 OCT 2018  
dd mm yyyy

## FOR DRUG SAFETY DEPARTMENT ONLY - NOT TO BE FILLED IN BY REPORTER:

Received date: 10-04-2018

Time: 21:38

Tracked: ☒

Case Number: VLN-5 July-2017-023-01

Signature:

(b) (6)